Sellside firefighting has saved the day for IGM, but Ash hears of some pretty potent anti-CD20 competition for the company.
The group had already fallen on its Ash abstract release, and today’s presentation offers little fresh hope.
Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.